Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
Marcolin R, Guolo F, Minetto P, Clavio M, Manconi L, Ballerini F, Carli A, Passannante M, Colombo N, Carminati E, Pugliese G, Tedone E, Contini P, Mangerini R, Kunkl A, Miglino M, Cagnetta A, Cea M, Gobbi M, Lemoli RM. Marcolin R, et al. Among authors: kunkl a. Leuk Res. 2019 Nov;86:106223. doi: 10.1016/j.leukres.2019.106223. Epub 2019 Sep 6. Leuk Res. 2019. PMID: 31557597
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Giannoni L, Ballerini F, Lemoli RM, Gobbi M, Miglino M. Minetto P, et al. Among authors: kunkl a. Am J Hematol. 2018 Feb;93(2):E33-E35. doi: 10.1002/ajh.24956. Epub 2017 Nov 17. Am J Hematol. 2018. PMID: 29080220 Free article. No abstract available.
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
Guolo F, Minetto P, Clavio M, Marcolin R, Miglino M, Passannante M, Caviglia F, Ballerini F, Tedone E, Kunkl A, Mangerini R, Contini P, Colombo N, Cagnetta A, Cea M, Carminati E, Pugliese G, Gobbi M, Lemoli RM. Guolo F, et al. Among authors: kunkl a. Leuk Lymphoma. 2020 Jul;61(7):1695-1701. doi: 10.1080/10428194.2020.1737685. Epub 2020 Mar 18. Leuk Lymphoma. 2020. PMID: 32186422
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
Guolo F, Di Grazia C, Minetto P, Raiola AM, Clavio M, Miglino M, Tedone E, Contini P, Mangerini R, Kunkl A, Colombo N, Pugliese G, Carminati E, Marcolin R, Passannante M, Bagnasco S, Galaverna F, Lamparelli T, Ballerini F, Cagnetta A, Cea M, Gobbi M, Bacigalupo A, Lemoli RM, Angelucci E. Guolo F, et al. Among authors: kunkl a. Eur J Haematol. 2021 Nov;107(5):573-582. doi: 10.1111/ejh.13694. Epub 2021 Aug 12. Eur J Haematol. 2021. PMID: 34297437
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.
Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A. Guolo F, et al. Among authors: kunkl a. Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. Haematologica. 2017. PMID: 28495917 Free PMC article. No abstract available.
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M. Minetto P, et al. Among authors: kunkl a. Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. Br J Haematol. 2019. PMID: 29359798 Free article. No abstract available.
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M. Guolo F, et al. Among authors: kunkl a. Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15. Am J Hematol. 2016. PMID: 27084986 Free article.
CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers.
Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, Contini P, Setti M, Olive D, Azzarone B, Carmignani G, Ravetti JL, Torre G, Indiveri F. Filaci G, et al. Among authors: kunkl a. J Immunol. 2007 Oct 1;179(7):4323-34. doi: 10.4049/jimmunol.179.7.4323. J Immunol. 2007. PMID: 17878327
Health technology assessment-based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification.
Gaipa G, Erba E, Danova M, Mazzini G, Venditti A, Buldini B, Specchia G, Maglia O, Kunkl A, Ciriello MM, Arpinati M, Mannelli F, Lanza F, Riccioni R, Pistotti V, Apolone G; Società Italiana di Citometria (GIC). Gaipa G, et al. Among authors: kunkl a. Tumori. 2020 Feb 14:300891620904412. doi: 10.1177/0300891620904412. Online ahead of print. Tumori. 2020. PMID: 32056511
66 results